RXi Pharmaceuticals Corp Share Price OTC Bulletin Board
Equities
US74979C1053
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | - | Sales 2025 * | 7.5Cr 626.37Cr | Capitalization | 23.21L 19Cr |
---|---|---|---|---|---|
Net income 2024 * | -90L -75Cr | Net income 2025 * | 4.7Cr 392.53Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.03 x |
P/E ratio 2024 * |
-0.28
x | P/E ratio 2025 * |
0.13
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.37% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/12/19 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/17/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/12/19 |
Director/Board Member | 73 | 02/22/02 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/13/18 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 4.66TCr | |
+45.38% | 4.17TCr | |
+0.69% | 4.12TCr | |
+30.52% | 3.24TCr | |
+22.30% | 2.82TCr | |
-6.35% | 2.81TCr | |
+49.25% | 1.45TCr | |
+49.18% | 1.37TCr | |
+3.45% | 1.22TCr |